Melatonin oral gel(Spherium Biomed SL)

Experts say medication commonly used to treat insomnia may also be a therapeutic option for the condition known as REM sleep behavior disorder. Mount Sinai researchers have published what they say is the first study to identify a new form of treatment for rapid eye movement (REM) sleep behavior disorder. This condition affects more than 3 million Americans, mostly adults over the age of 50, who often unknowingly physically act out their dreams with vocal sounds or sudden, violent arm and leg movements during slumber, leading to significant injury to themselves or bed partners. The new study, published in the Journal of Neuroscience on May 25, outlines a novel model to better characterize how REM sleep behavior disorder develops due to neurodegeneration -- when brain cells lose function over time -- which is associated with the accumulation of tau protein. This model provides an early-life biomarker of impending deterioration of the brain, which could guide future prevention and treatment. The paper also demonstrates for the first time that sleep medications known as dual orexin receptor antagonists -- commonly used to treat insomnia, or difficulty falling and remaining asleep -- can significantly reduce REM sleep behavior disorder. Current therapeutic options for this disorder are primarily limited to melatonin and clonazepam, also known as Klonopin, so these findings suggest a promising new treatment with potentially fewer side effects. "We were interested in understanding all of the ways in which sleep quality breaks down as neurodegeneration progresses and whether there were any ways to mitigate such changes," said corresponding author Andrew W. Varga, MD, PhD, Associate Professor of Medicine (Pulmonary, Critical Care and Sleep Medicine) at the Icahn School of Medicine at Mount Sinai. "We identify a novel model in which REM sleep behavior disorder can develop, due to neurodegeneration associated with accumulation of tau protein, and a novel therapy that could minimize REM sleep behavior disorder." Mount Sinai researchers used a mouse model to study neurodegenerative disorders by examining the brain following abnormal deposits of tau, a protein that normally helps stabilize the internal skeleton of nerve cells in the brain. They analyzed behavioral states including wakefulness, phases of REM (sleep with dreams), phases of non-REM (sleep without dreams), length of sleep, transitions from waking to sleep, and how some factors are related to age. Nearly a third of the older subjects exhibited dream enactment behaviors reminiscent of REM sleep behavior disorder, including chewing and limb extension. After administering a dual orexin receptor antagonist twice during a 24-hour period, to evaluate sleep in light and dark phases, the researchers observed that the medication not only reduced the time it took to fall asleep and increased both the quality and duration of sleep but also reduced levels of dream enactment. Researchers hope their findings will encourage future trials of dual orexin receptor antagonists to treat REM sleep behavior disorder in humans, given that the medication is already FDA approved and available to treat people with insomnia. "We anticipated finding breakdown of sleep quality with progressive neurodegeneration related to tau accumulation, but the observation of dream enactment was a surprise," said lead author Korey Kam, PhD, Assistant Professor of Medicine (Pulmonary, Critical Care and Sleep Medicine) at Icahn Mount Sinai. "It was even more surprising and exciting to observe that a dual orexin receptor antagonist could significantly minimize the dream enactment behaviors." The research was supported by funding from the Alzheimer's Association and Merck Investigator Studies Program.

VANCOUVER, BC, May 3, 2023 /PRNewswire/ - Hapbee Technologies, Inc. (TSXV: HAPB) (OTCQB: HAPBF) (FSE: HA1) ("Hapbee" or the "Company") the wearable, wellness technology company and creator of the Hapbee Smart Sleep Pad, has announced a partnership with Reputable Health to develop customized sleep routines which would be accessible through Hapbee products and are derived from A.I.-driven algorithms that will analyze consumers' sleep data gathered through the Reputable Health platform. Hapbee's patented biostreaming technology helps people optimize their sleep, performance, and moods. Ultra-low electro-magnetic frequency biostreams are derived from compounds like caffeine, nicotine and melatonin which are delivered digitally through Hapbee-powered devices; such as, the Smart Sleep Pad and Neckband without the side-effects or dependencies that might otherwise result from ingesting the substances. Reputable Health is an AI-powered health optimization platform that provides recommendations based on real-world data. Through their partnership, Hapbee and Reputable Health will work together to offer a comprehensive, individualized, digital wellness solution to Hapbee users, starting with sleep health. Reputable Health's AI-powered platform will aggregate anonymized health data from wearables, lab tests, genomics and health experiments to offer personalized recommendations to Hapbee users based on their unique health goals. By leveraging the power of Hapbee's ulRFE® technology and cutting-edge health analytics, Hapbee and Reputable Health aim to empower users to achieve their sleep goals, including helping users to fall asleep faster, stay asleep all-night, and wake up refreshed in the morning. According to Hapbee CEO Yona Shtern, "Partnering with Reputable Health will enable us to continue to innovate our next-gen wellness solution with a personalized experience, optimized based on the users' own real-world data, allowing them to impact their wellness in a way that is uniquely tailored to their individual needs. We are excited to work with Reputable Health to help our users achieve their health and wellness goals." Reputable Health Head of Operations & Business Development Dr. Kyle Bergquist added, "Our partnership with Hapbee is a natural fit, as both companies are focused on empowering individuals to take control of their health and wellness. By combining our AI-powered platform with Hapbee's unique digital wellness technology, we will be able to provide users with personalized recommendations that are based on real-world data, enabling them to achieve their health and wellness goals more effectively." The partnership between Hapbee and Reputable Health is an exciting development for anyone who wants to optimize their wellness. Together, the two companies seek to empower users to take control of their wellness in a way that is tailored to their individual needs. Hapbee confirms that it has received confirmation from the BC Securities Commission that it has completed the review and approved the Management Cease Trade Order effective May 2, 2023, under National Policy 12-203 (the "Policy") pending the filing of the Required Disclosure via SEDAR. Hapbee is confident that the Required Disclosure will be filed by no later than June 30, 2023. The Management Cease Trade Order is imposed against the Company's chief executive officer, and its chief financial officer. There has been no cease trade order imposed against all securities of Hapbee. The MCTO will not generally affect the ability of other persons to trade the securities of Hapbee pending the filing of the Required Disclosure via SEDAR. Hapbee intends to comply with the provisions of the Alternative Information Guidelines as set out in the Policy for as long as it remains in default, including the issuance of bi-weekly default status reports, if necessary, each of which will be issued in the form of a press release. Hapbee is not subject to any insolvency proceeding and there is no other material information concerning the affairs of Hapbee that has not been generally disclosed. About Reputable Health Reputable Health is an AI-powered health optimization platform that provides recommendations based on real-world data. It empowers its community to take control of their health and make informed decisions without having to rely on fake online reviews, social media hype and murky science. Reputable aggregates anonymized data from wearables, lab tests, genomics and health experiments, and rewards participants who contribute, enabling fair and equitable value sharing for everyone. For more information about Reputable, visit: Follow Reputable on Twitter and LinkedIn About Hapbee Hapbee is a digital wellness technology company that aims to help people take control of how they sleep, perform and feel. Hapbee's digital wellness library of Wellness Routines utilizes patented ultra-low radio frequency energy (ulRFE®), designed to help optimize users' sleep, productivity and focus, recovery, and downtime. Hapbee devices and subscriptions are available for purchase at Hapbee.com, on Amazon.com and through a growing network of select distributors. You can learn more about how Hapbee works at Forward-Looking Statements Certain statements included in this news release constitute forward-looking information or statements (collectively, "forward-looking statements"), including those identified by the expressions "anticipate", "believe", "plan", "estimate", "expect", "intend", "may", "should" and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This news release contains forward-looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Any statements pertaining to the anticipated filing date for the Filings, as well as statements pertaining the expected timeline for the MCTO to be lifted are forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions which are difficult to predict. Such statements and information are based on numerous assumptions regarding the Company's ability and intended timing to complete its Filings. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement, and are subject to various risks, uncertainties and assumptions which include, but are not limited to, those described in Hapbee's annual information form dated May 2, 2022, as well as those described in Hapbee's other disclosure documents, copies of which are available on SEDAR at , and could cause actual events or results to differ materially from those projected in any forward-looking statements. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Readers should not place undue reliance on the Company's forward-looking statements. Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. SOURCE Hapbee Technologies Inc.